Have an account? Log in to check out faster.
Retatrutide (IGF1-LR3) is a next-generation peptide that targets three key metabolic receptors—GIP, GLP-1, and glucagon—to drive powerful, sustained fat loss.
In recent trials, users experienced up to 17.5% weight loss in just 24 weeks. This innovative formula not only boosts fat metabolism but also supports better appetite control and insulin sensitivity.
IGF1-LR3 boosts fat metabolism in an indirect manner by binding to both the IGF-1R receptor and the insulin receptor. These actions increase glucose uptake from the blood by muscle, nerve, and liver cells. This results in an overall decrease in blood sugar levels, which then triggers adipose tissue as well as the liver to begin breaking down glycogen and triglycerides. Overall, this produces a net decrease in adipose tissue and a net energy consumption (i.e. net catabolism).
Given its role in reducing blood sugar levels, it should come as no surprise that IGF1-LR3 reduces insulin levels as well as the need for exogenous insulin in diabetes. In most cases, this translates into a 10% decrease in insulin requirements to maintain the same blood sugar levels. This fact may help scientists understand how to decrease insulin doses in individuals who have decreased insulin sensitivity and may even offer insight into preventing type 2 diabetes in the first place.
Reconstitute using bacteriostatic water within a pH range of 5.7 to 7.0.
Each vial contains 20mg of ultra-pure Retatrutide (99.3%+ purity).
Disclaimer:
This compound is supplied strictly for research use only.
It is not intended for human consumption, medical, or therapeutic use.
By purchasing, you confirm you are a qualified researcher handling this material responsibly and in accordance with all applicable laws and regulations.